ERBB2 and breast cancer: The results of the present study extend our previous findings demonstrating that, at diagnosis, patients with locally advanced, HER2-overexpressing BC are characterized by a retained immune proficiency [23], and more importantly, achieve a high rate of pCR (42.5%) after neoadjuvant Trastuzumab and Paclitaxel [35].